PolyPeptide Group AG shares hit a more than three-year high after reports that the Swiss contract drugmaker is drawing private equity takeover interest. The news points to potential M&A optionality and has already lifted the stock materially. No deal terms, bidder identity, or premium were disclosed.
PolyPeptide Group AG shares hit a more than three-year high after reports that the Swiss contract drugmaker is drawing private equity takeover interest. The news points to potential M&A optionality and has already lifted the stock materially. No deal terms, bidder identity, or premium were disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
